Sequential bounce masks YoY collapse; H2 growth guidance untested
Revenue rebounded 12.9% quarter-over-quarter to ₹476.6 Cr, but the year-on-year picture is brutal: -14.2% revenue, -96.6% net profit. The company promised H2 would return to growth. Q2 is not the foundation for that claim.
₹476.6 Cr
+12.9% QoQ / -14.2% YoY
0.5%
₹2.3 Cr PAT, -96.6% YoY
7.4%
vs. 9.2% guidance
On the surface, sequential revenue recovery (+12.9% QoQ to ₹476.6 Cr) and reaffirmed H2 guidance for YoY growth sound constructive. But the year-on-year picture is unforgiving. Revenue down 14.2%, net profit down 96.6% to just ₹2.3 Cr. The company claimed the quarter prior that H2 FY27 would be the growth inflection; Q2 is not the foundation for that—it is counter-evidence.
Where the profit gap came from
Management claims adjusted EBITDA margin around 10% (approximately ₹48 Cr), but reported net margin is 0.5% (₹2.3 Cr PAT). The reconciliation: ₹45+ Crore in D&A and interest burden sits between EBITDA and net profit. This is not accounting noise. Capex deployment (₹100 Cr in H1 tracking toward ₹300 Cr for FY27) and gross debt (~₹23 Cr) are real structural drains. Until margin recovery is evident in reported earnings, EBITDA adjustments remain narrative convenience rather than cash generation.
Sequential revenue growth 13% signals recovery trajectory
Q2 ₹476.6 Cr up 12.9% QoQ, but down 14.2% YoY vs prior year
Overstated
H2 will deliver YoY growth on revenue and EBITDA
Q2 missed YoY (-14.2%); H2 must overcome deeper trough. Unproven.
Unverified
Adjusted EBITDA margin improving to around 10%
Reported OPM 7.4%, NPM 0.5%; high D&A/interest burden obscures operational leverage
Contradicted
Pharma CDMO momentum secured with three new pharma contracts
Pharma CDMO down 27% YoY in Q2. Contracts have 18–36M lead times; not near-term revenue drivers.
Supported (timing issue)
ADC development funnel moving in right direction
Two ADC GMP campaigns completed Q2. Destocking ongoing. Progress real but early-stage; no revenue yet.
Supported
What changed on this call
Three material shifts from prior guidance. First: margin recovery is now vague. Prior call specified 9.2% standalone margin guidance; this quarter management declined to quantify the path forward, saying only 'sequential improvement.' That is a de facto downgrade. Second: Suryapet facility closure was newly disclosed (order in place; revenue impact unquantified; management evaded timelines). A known operational risk not pre-disclosed. Third: three new pharma contracts announced, but with 18–36 month lead times, pushing material upside into FY28–FY29, not H2. The contracts confirm Cohance's platform appeal but do not solve near-term headwinds.
Segment reality check
The bright spot: Niche Technologies (Sapala nucleic acids) is growing 33% YoY and now represents 14% of revenue. The drag: Pharma CDMO (-27% YoY) and Specialty Chemicals (-40.6% YoY) together create a -700+ basis point headwind on consolidated margin. API+ stabilizing at +5% YoY growth is adequate but not sufficient to offset the destocking in adjacent segments.
Bull-bear ledger
ADC platform and bioconjugation capability (NJ Bio) now proven; two GMP campaigns completed
Sapala nucleic acid program growing 33% YoY; Phase III sampling underway with two innovators
Three new pharma contracts from large innovators signal deep customer relationships and platform validation
Capex deployed ₹100 Cr in H1; strategic investments in adjacent modalities (ADC, nucleic acid infrastructure)
Pharma CDMO down 27% YoY; destocking cycle timeline unspecified; could extend into FY28
Specialty Chemicals down 40.6% YoY; structural exposure to generic crop protection pricing pressure
Margin recovery path vague; 9.2% guidance not re-affirmed; raw material inflation unquantified
USFDA classification pending (1–3 months); adverse outcome could restrict facility capacity utilization
Suryapet facility closure order issued; execution timeline and revenue impact unquantified
Three new pharma contracts have 18–36M lead times; near-term revenue uplift minimal
Risks ranked by holder concern
H2 YoY growth guidance unproven; Q2 missed badly (-14.2% YoY revenue)
HIGHIf H2 does not deliver promised growth, guidance credibility erodes and margin recovery narrative collapses. Execution risk is material.
Pharma CDMO destocking persists longer than H2; two commercial programs in correction cycle
HIGH27% YoY decline in Q2. If destocking extends into FY28, consolidated margin stays compressed; three new contracts are 18–36M out, offering no near-term offset.
USFDA classification decision pending within 1–3 months; adverse outcome restricts capacity
HIGHThree API facilities under inspection. If classification is unfavorable, remediation timelines and capex requirements unknown. Could delay H2 order fulfillment.
Suryapet facility closure order in place; revenue impact and timeline unquantified
HIGHKnown operational risk not pre-disclosed. Regulatory uncertainty cited as reason for non-disclosure. Signals execution risk and near-term earnings volatility.
Margin recovery path vague; management declined quantified targets; 9.2% guidance missed (7.4% delivered)
HIGHLow confidence in recovery pace or magnitude. If raw material inflation persists or CDMO destocking deepens, margins stay compressed longer than H2 claim.
Specialty Chemicals down 40.6% YoY; structural exposure to generic crop protection pricing
MEDIUMLegacy portfolio under pressure. Stabilization claimed but not evidenced. Could be a sustained drag on consolidated mix if agriculture remains soft.
How the street is positioned
Price action and valuation: Cohance trades at ₹464.1 as of Nov 11, above its 20-day, 50-day, and 200-day moving averages—a bullish trend signal. However, the stock remains down 65.88% from its all-time high of ₹1,360, though it has recovered 74% from its 52-week low. The post-result bounce has held: the stock sits firmly in its 52-week range (₹266.7–₹744.3), suggesting the market is digesting the mixed quarter without panic repricing. Valuation context: the stock has been heavily corrected from prior peak, so recovery from current levels is plausible if execution improves; a further breakdown would signal loss of faith in H2 guidance.
Institutional flows: FII holdings increased to 6.50% in Q1 FY-2027 (from 5.59% in Q4 FY-2026), suggesting modest foreign accumulation post-result—a modest constructive signal. DII trimmed 1.7 percentage points to 20.09%, indicating domestic institutional profit-taking or portfolio rebalancing. Promoter stake unchanged at 57.49%.
Insider/bulk activity: Recent bulk deal (Nov 9, 2026) saw 30 million shares trade at ₹430 between JASTI FAMILY TRUST and JASUB PROPERTY HOLDINGS LLP. This appears to be a related-party reallocation rather than insider selling pressure; no red flag, but worth monitoring for any future related-party capital movements that might signal management confidence erosion.
1 · H2 order visibility and revenue run-rate (Q3 FY27 earnings)
The core question: Does management deliver the promised YoY growth after Q2's -14.2% miss? Track quarterly revenue trajectory and CDMO destocking status. If H2 Q3 shows YoY growth, guidance gains credibility. If it doesn't, the bear case accelerates.
2 · USFDA classification decision (expected Dec 2026–Mar 2027)
Three API facilities await FDA classification. Favorable outcome = capacity preserved and H2 orders on track. Adverse outcome = remediation timelines, capex requirements, and potential capacity constraints. This binary event gates H2 execution.
3 · Margin recovery path quantified (Q3 earnings call)
Management must move beyond 'sequential improvement' and commit to a specific margin target and timeline. Continued vagueness signals low confidence and execution risk. OPM recovery toward 9–10% range is the proxy for operational leverage from strategic initiatives.
This is steady-state execution under pressure, not a step-change. Cohance is repositioning into higher-margin niches (ADCs, nucleic acids) and building deeper pharma relationships (three new contracts), but near-term operational headwinds are acute and underestimated by management. The margin miss (7.4% OPM vs. 9.2% guidance), the YoY revenue collapse (-14.2%), and the H2 growth claim not yet evidenced in Q2 all point to execution risk.
The key number to track from here is H2 FY-2027 revenue growth—does the company deliver the promised YoY inflection or continue the deterioration? Paired with the USFDA classification decision (a binary gating event) and margin recovery credibility (specific targets or continued evasion), these will determine whether Cohance's strategic narrative gains legs or erodes further. Until management demonstrates quarterly YoY growth and quantifies margin recovery, position this as a recovery play with high execution risk.
Informational and educational content only. Not investment advice.